Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences' stock price has experienced significant fluctuations in the past six months. The share price as of January 2, 2026, was $3.47, a substantial decline from $10.50 on January 6, 2025. Key events include Q3 2025 financial results with an EPS of -$1.41, exceeding expectations, confirmation of EU Conditional Approval Eligibility for iopofosine I 131, a strategic supply agreement with Ionetix for Actinium-225 and Astatine-211, and strategic initiatives highlighted at the Biotech Showcase during the 44th Annual JP Morgan Healthcare Conference. Insider trading activity shows more stock sold than bought in the past three months, but significant insider purchases over the last year. Analyst ratings include an upgrade to "Buy" in July 2025, but the consensus rating is currently "Hold."

Information regarding the demand seasonality specifically for Cellectar Biosciences' products and services is not available. The company is a clinical-stage biopharmaceutical company, meaning its primary focus is on research, development, and clinical trials rather than commercial sales of approved products. Stock returns show monthly seasonality, with February having the highest probability of a positive return and October the lowest.

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies and imaging agents using its proprietary Phospholipid Drug Conjugate (PDC) platform. The company's lead product, Iopofosine I 131, is being evaluated in Phase II clinical trials for relapsed or refractory B-cell malignancies and in a pivotal expansion cohort for Waldenstrom's macroglobulinemia (WM), and has received FDA Breakthrough Therapy Designation for WM and Orphan Drug Designation for multiple myeloma. Cellectar is also developing CLR 1501 and CLR 1502, fluorescent and near-infrared imaging probes, CLR 121225, an actinium-225 based alpha-emitting radioconjugate program, and CLR 121125, an iodine-125 Auger-emitting program.

Cellectar Biosciences, Inc. is headquartered in Florham Park, New Jersey, United States. Its clinical studies for iopofosine I 131 are global, including a pivotal expansion cohort for Waldenstrom's macroglobulinemia and a Phase 1 pediatric study in North America. The company is pursuing regulatory pathways in Europe and holds a broad U.S. and international intellectual property rights portfolio for its PDC technology.

Cellectar Biosciences has a news sentiment score of 0.96, with increased news articles recently. The company's MarketRank™ score is higher than 35% of companies in the medical sector. Regulatory progress for Iopofosine I 131, positive earnings reports, strategic partnerships with Ionetix, and analyst coverage have likely influenced the company's reputation positively.

Cellectar Biosciences is owned by a mix of institutional shareholders, insiders, and retail investors. Institutions hold 6.98% of the stock, with major holders including Fidelity Extended Market Index Fund and Vanguard Group Inc. Insiders own 79.20% of the company, with Austin W. Greenhouse David M. Marxe being the largest individual shareholder. Retail investors own 13.82% of the stock.